Parkman Healthcare Partners
$974M 13F equity value
106 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Parkman Healthcare Partners covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| MBX | MBX BIOSCIENCES INC | 800,173 | $44M | 4.5% |
| LLY | ELI LILLY & CO | 35,000 | $42M | 4.3% |
| CVS | CVS HEALTH CORP | 391,791 | $41M | 4.2% |
| DXCM | DEXCOM INC | 534,767 | $36M | 3.7% |
| PTCT | PTC THERAPEUTICS INC | 435,691 | $36M | 3.6% |
| RCUS | ARCUS BIOSCIENCES INC | 919,266 | $28M | 2.9% |
| GPCR | STRUCTURE THERAPEUTICS INC | 485,661 | $26M | 2.7% |
| VRDN | VIRIDIAN THERAPEUTICS INC | 1,377,576 | $25M | 2.6% |
| AGIO | AGIOS PHARMACEUTICALS INC | 669,046 | $25M | 2.5% |
| INBX | INHIBRX BIOSCIENCES INC | 256,950 | $24M | 2.5% |
Track Parkman Healthcare Partners's 13F portfolio: $974M in reported holdings, 106 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}